Skip to content
The Nexus
DossierENTITY

Atara Biotherapeutics

Coverage of Atara Biotherapeutics in the Nexus archive.

Earliest in view: May 7 · 12:00 UTCMost recent: May 7 · 12:00 UTC
Co-mentioned in this coverage
Pierre Fabre Pharmaceuticalsorganization1Food and Drug Administrationorganization1Vinay Prasadperson1Ebvallotopic1FDA's Center for Biologics Evaluation and Researchorganization1
Recent coverage
  • HEALTHMay 7 · 12:00 UTCSTAT NEWS
    STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection

    The FDA has agreed to reconsider a treatment for a rare blood cancer called Ebvallo after initially rejecting it in January. The drug's manufacturers, Pierre Fabre Pharmaceuticals and Atara Biotherapeutics, had a meeting with FDA officials in late April. The agency will now review the already completed clinical trial.

Atara Biotherapeutics · Dossier · The Nexus